全文获取类型
收费全文 | 570155篇 |
免费 | 300745篇 |
国内免费 | 57008篇 |
专业分类
耳鼻咽喉 | 5451篇 |
儿科学 | 7612篇 |
妇产科学 | 7172篇 |
基础医学 | 128535篇 |
口腔科学 | 7931篇 |
临床医学 | 104432篇 |
内科学 | 142482篇 |
皮肤病学 | 7786篇 |
神经病学 | 38737篇 |
特种医学 | 20173篇 |
外国民族医学 | 224篇 |
外科学 | 75160篇 |
综合类 | 101947篇 |
现状与发展 | 78篇 |
一般理论 | 23篇 |
预防医学 | 60293篇 |
眼科学 | 25571篇 |
药学 | 89112篇 |
357篇 | |
中国医学 | 62042篇 |
肿瘤学 | 42790篇 |
出版年
2023年 | 7047篇 |
2022年 | 16180篇 |
2021年 | 19637篇 |
2020年 | 17777篇 |
2019年 | 23425篇 |
2018年 | 24595篇 |
2017年 | 23752篇 |
2016年 | 21780篇 |
2015年 | 26603篇 |
2014年 | 29676篇 |
2013年 | 27655篇 |
2012年 | 35434篇 |
2011年 | 39836篇 |
2010年 | 32108篇 |
2009年 | 36224篇 |
2008年 | 28840篇 |
2007年 | 25848篇 |
2006年 | 25429篇 |
2005年 | 25268篇 |
2004年 | 20641篇 |
2003年 | 19055篇 |
2002年 | 17923篇 |
2001年 | 18832篇 |
2000年 | 15288篇 |
1999年 | 21220篇 |
1998年 | 19066篇 |
1997年 | 18939篇 |
1996年 | 18726篇 |
1995年 | 18569篇 |
1994年 | 17746篇 |
1993年 | 15350篇 |
1992年 | 15460篇 |
1991年 | 14392篇 |
1990年 | 13086篇 |
1989年 | 12677篇 |
1988年 | 11922篇 |
1987年 | 11123篇 |
1986年 | 10419篇 |
1985年 | 9356篇 |
1984年 | 7039篇 |
1983年 | 6889篇 |
1982年 | 7818篇 |
1981年 | 7314篇 |
1980年 | 6945篇 |
1979年 | 6839篇 |
1978年 | 5886篇 |
1977年 | 6195篇 |
1976年 | 5802篇 |
1975年 | 5533篇 |
1974年 | 5128篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
31.
32.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献
33.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
34.
目的:探讨风险管理在护理管理中的应用效果。方法:选取2012年8月~12月实施风险管理前于我科接受手术治疗患者180例作为对照组;2014年1月~5月于我科接受手术治疗的210例患者作为观察组,对实施护理风险管理前后患者对护理工作者工作质量的评价、护理工作者应急能力等指标进行比较。结果:1护理质量:风险管理应用到护理管理中,患者投诉情况、护理不良事件发生情况以及满意情况均优于应用前(P<0.05)。2工作质量:风险管理应用后,护理工作人员在责任心、沟通能力、服务态度以及操作熟练程度方面评分均显著高于应用前,P<0.05。3风险意识:风险管理应用后,护理工作者对于风险管理、风险因素的认识,风险管理态度以及应急能力均较之于应用前显著提高。结论:风险管理应用于护理管理,可降低护理纠纷,提高患者护理满意度。 相似文献
35.
36.
37.
Context: Baicalin has many pharmacological activities, including protective function against myocardial ischemia by antioxidant effects and free radical scavenging activity. However, its rapid elimination half-life in plasma and poor water solubility limits its clinical efficacy.Objective: Novel baicalin-loaded PEGylated nanostructured lipid carriers (BN-PEG-NLC) were developed to improve bioavailability of BN, to prolong retention time in vivo and to enhance its protective effect.Methods: In this study, BN-PEG-NLC were prepared by the emulsion-evaporation and low temperature-solidification method using a mixture of glycerol monostearate and polyethylene glycol monostearate as solid lipids, and oleic acid as the liquid lipid. The physicochemical properties of NLC were characterized. The pharmacokinetic and pharmacodynamic behaviors of BN-PEG-NLC or BN-NLC were evaluated in acute MI rats.Results and discussion: The particle size, zeta potential, and entrapment efficiency for BN-PEG-NLC were observed as 83.9?nm, ?32.1?mV, and 83.5%, respectively. The release profiles of BN from both BN-PEG-NLC and BN-NLC were fitted to the Ritger–Peppas modal, which presented burst release initially and prolonged release afterwards. Pharmacokinetics results indicated that BN-PEG-NLC exhibited a 7.2-fold increase in AUC in comparison to BN solution, while a 3-fold increase in comparison to BN-NLC. Biodistribution results revealed that BN-PEG-NLC exhibited higher heart drug concentration compared with BN-NLC as well as BN solution. In the present study, BN-PEG-NLC significantly ameliorated infarct size.Conclusion: The results of the present study imply that PEG-NLC could be the biocompatible carriers for heart-targeted drug delivery to improve myocardial ischemia. 相似文献
38.
39.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
40.
目的分析成人血液系统恶性肿瘤患者接受强烈化疗后中性粒细胞减少性肠炎(NE)的发生率、危险因素及预后情况。方法收集2004至2013年接受化疗的1804例血液系统恶性肿瘤患者,记录患者血常规、凝血检测和血液生化检测结果,并记录患者年龄、性别、原发病、既往化疗次数、既往化疗方案中是否使用阿糖胞苷、临床症状、肠壁厚度、中性粒细胞最低计数、中性粒细胞缺乏持续时间、NE的治疗方法和预后等,探讨NE起病诱因、临床特征、腹部B超特点、症状的预后意义及化疗药物对发病的影响等。结果1804例患者中226例(12.5%)化疗后合并NE,化疗后10~19d起病,中位起病时间为化疗后第14天。发生NE后26例患者死亡,病死率11.5%。化疗药物包括阿糖胞苷、临床症状≥4项、中性粒细胞缺乏持续超过7d以及B超下肠壁厚度≥10mm的患者病死率相对较高。结论NE是接受强烈化疗的血液系统肿瘤患者的严重的并发症,发生NE后患者病死率较高。 相似文献